Article Data

  • Views 307
  • Dowloads 127

Mini-Reviews

Open Access

Phase III clinical trials of radical hysterectomy with minimal parametrectomy for patients with early-stage cervical cancer: a review

  • Takahiro Kasamatsu1,*,
  • Takahide Arimoto2

1Department of Obstetrics and Gynecology, Tokyo Metropolitan Bokutoh Hospital, 130-8575 Tokyo, Japan

2Department of Obstetrics and Gynecology, Toranomon Hospital, 105-8470 Tokyo, Japan

DOI: 10.22514/ejgo.2022.026 Vol.43,Issue 4,August 2022 pp.12-18

Submitted: 22 May 2022 Accepted: 13 July 2022

Published: 15 August 2022

*Corresponding Author(s): Takahiro Kasamatsu E-mail: ugk46778@nifty.com

Abstract

The standard surgery for patients with International Federation Gynecology and Obstetrics (FIGO) stage IB–II cervical cancer is a Piver-Rutledge-Smith class III radical hysterectomy with pelvic lymphadenectomy involving a wide resection of parametrial and paravaginal tissue to control parametrial involvement. However, adverse events can occur such as severe long-term neurogenic bladder due to parametrectomy. This review evaluates ongoing and completed phase III clinical trials of less radical hysterectomy with regard to parametrectomy. The PubMed database, Clinical Trials.gov, and Cochrane Central Register of Controlled Trials were used to extract information on two completed and four ongoing clinical trials. Less radical surgery led to similar oncologic outcomes to standard surgery in two phase III randomized controlled trials (Piver class II vs. class III, and class I vs. class III radical hysterectomy with pelvic lymphadenectomy). Less radical surgery also led to fewer complications, including urologic morbidity; however, more than 50% of patients received radiotherapy following such surgery, and showed higher morbidity rates because their enrolment was due to the presence of a large tumor (>4 cm). Three phase III randomized controlled trials and a phase III nonrandomized confirmatory trial are presently ongoing. Major inclusion criteria include FIGO stage IA, IB, or IIA1, a mainly ≤2-cm tumor, limited depth of stromal invasion, and/or no lymph node metastasis. Surgery for the standard arm is a class II or class III radical hysterectomy, and the experimental surgery is a simple extrafascial hysterectomy or class II radical hysterectomy. Primary endpoints are overall, disease-free, or recurrence-free survival. Although primary endpoints, eligibilities or types of radical hysterectomy differ between trials, if noninferiority in overall, disease-free or recurrence-free survival is observed in any trial, new standard, less radical, curative hysterectomy may be established for early-stage, small-sized, invasive, cervical cancer.


Keywords

Early-stage cervical cancer; Less radical hysterectomy; Parametrectomy; Tumor size; Phase III clinical trial


Cite and Share

Takahiro Kasamatsu,Takahide Arimoto. Phase III clinical trials of radical hysterectomy with minimal parametrectomy for patients with early-stage cervical cancer: a review. European Journal of Gynaecological Oncology. 2022. 43(4);12-18.

References

[1] Piver MS, Rutledge F, Smith JP. Five classes of extended hysterectomy for women with cervical cancer. Obstetrical & Gynecological Survey. 1975; 30: 220–223.

[2] Kasamatsu T, Onda T, Sawada M, Kato T, Ikeda S, Sasajima Y, et al. Radical hysterectomy for FIGO stage I–IIB adenocarcinoma of the uterine cervix. British Journal of Cancer. 2009; 100: 1400–1405.

[3] Kasamatsu T, Onda T, Sawada M, Kato T, Ikeda S. Radical hysterectomy for FIGO stage IIB cervical cancer: clinicopathological characteristics and prognostic evaluation. Gynecologic Oncology. 2009; 114: 69–74.

[4] Bandy LC, Clarke-Pearson DL, Soper JT, Mutch DG, MacMillan J, Creasman WT. Long-term effects on bladder function following radical hysterectomy with and without postoperative radiation. Gynecologic Oncology. 1987; 26: 160–168.

[5] Scotti RJ, Bergman A, Bhatia NN, Ostergard DR. Urodynamic changes in urethrovesical function after radical hysterectomy. Obstetrics & Gynecology. 1986; 68: 111–120.

[6] Zanolla R, Monzeglio C, Campo B, Ordesi G, Balzarini A, Martino G. Bladder and urethral dysfunction after radical abdominal hysterectomy: rehabilitative treatment. Journal of Surgical Oncology. 1985; 28: 190–194.

[7] Carenza L, Nobili F, Giacobini S. Voiding disorders after radical hysterectomy. Gynecologic Oncology. 1982; 13: 213–219.

[8] Landoni F, Maneo A, Cormio G, Perego P, Milani R, Caruso O, et al. Class II versus class III radical hysterectomy in stage IB–IIA cervical cancer: a prospective randomized study. Gynecologic Oncology. 2001; 80: 3–12.

[9] Landoni F, Maneo A, Zapardiel I, Zanagnolo V, Mangioni C. Class I versus class III radical hysterectomy in stage IB1–IIA cervical cancer. a prospective randomized study. European Journal of Surgical Oncology. 2012; 38: 203–209.

10] Clinical Trials.gov. Explore 421,553 research studies in all 50 states and in 221 countries. 2022. Available at: https://clinicaltrials.gov (Accessed: 18 January 2022).

[11] Japan Registry of Clinical Trials. 2022. Available at: https://jrct. niph.go.jp/ (Accessed: 18 January 2022).

[12] Kunieda F, Kasamatsu T, Arimoto T, Onda T, Toita T, Shibata T, et al. Non-randomized confirmatory trial of modified radical hysterectomy for patients with tumor diameter 2 cm or less FIGO Stage IB1 uterine cervical cancer: Japan clinical oncology group study (JCOG1101). Japanese Journal of Clinical Oncology. 2015; 45: 123–126.

[13] Kato T, Takashima A, Kasamatsu T, Nakamura K, Mizusawa J, Nakanishi T, et al. Clinical tumor diameter and prognosis of patients with FIGO stage IB1 cervical cancer (JCOG0806-A). Gynecologic Oncology. 2015; 137: 34–39.

[14] Sun H, Cao D, Shen K, Yang J, Xiang Y, Feng F, et al. Piver type II vs. type III hysterectomy in the treatment of early-stage cervical cancer: midterm follow-up results of a randomized controlled trial. Frontiers in Oncology. 2018; 8: 568.

[15] Querleu D, Morrow CP. Classification of radical hysterectomy. The Lancet Oncology. 2008; 9: 297–303.

[16] Averette HE, Nguyen HN, Donato DM, Penalver MA, Sevin B, Estape R, et al. Radical hysterectomy for invasive cervical cancer: a 25-year prospective experience with the Miami technique. Cancer. 1993; 71: 1422–1436.

[17] Bergmark K, Avall-Lundqvist E, Dickman PW, Henningsohn L, Steineck G. Vaginal changes and sexuality in women with a history of cervical cancer. New England Journal of Medicine. 1999; 340: 1383–1389.

[18] Zullo MA, Manci N, Angioli R, Muzii L, Panici PB. Vesical dysfunctions after radical hysterectomy for cervical cancer: a critical review. Critical Reviews in Oncology/Hematology. 2003; 48: 287–293.

[19] Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. New England Journal of Medicine. 2018; 379: 1895–1904.

[20] Kasamatsu T, Ishikawa M, Murakami N, Okada S, Ikeda S, Kato T, et al. Identifying selection criteria for non-radical hysterectomy in FIGO stage IB cervical cancer. Journal of Obstetrics and Gynaecology Research. 2019; 45: 882–891.

[21] Covens A, Rosen B, Murphy J, Laframboise S, DePetrillo AD, Lickrish G, et al. How important is removal of the parametrium at surgery for carcinoma of the cervix? Gynecologic Oncology. 2002; 84: 145–149.

[22] Derks M, van der Velden J, de Kroon CD, Nijman HW, van Lonkhuijzen LRCW, van der Zee AGJ, et al. Surgical treatment of early-stage cervical cancer: a multi-institution experience in 2124 cases in the Netherlands over a 30-year period. International Journal of Gynecologic Cancer. 2018; 28: 757–763.

[23] National Comprehensive Cancer Network. 2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf (Accessed:18 January 2022).


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top